Bevacizumab
Monoclonal antibody targets VEGFA
Regulatory milestones approvals, filings & regulatory actions · 20 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Refused (EMA) | EU (EMA) | Ipique | — | 2022-04-29 | europa.eu ↗ |
| Label expansions (2) | US (FDA) | MVASI | — | 2019-06-24 – 2021-11-15 | fda.gov ↗ |
| Label expansions (15) | US (FDA) | AVASTIN | — | 2005-09-29 – 2020-05-29 | fda.gov ↗ |
| Approved | EU (EMA) | Avastin | — | 2005-01-12 | europa.eu ↗ |
| Approved | US (FDA) | AVASTIN | — | 2004-02-26 | fda.gov ↗ |
Trials 2,017 · started per year
Also used as a comparator or background therapy in 712 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 08 trials | ||||||
| Phase 0 | NCT07318389 Background | Jun 2026 → Nov 2027 expected | colorectal cancer | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06011772 Background | Dec 2023 → Feb 2026 overdue | colorectal cancer | Roswell Park Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 0 | NCT03554707 Background | Jun 2022 | central nervous system cancer | SynerGene Therapeutics, Inc. | Withdrawn | No outcome recorded |
| Phase 0 | NCT05053750 Background | Dec 2021 → Feb 2027 expected | fallopian tube neoplasm, malignant epithelial tumor of ovary, primary peritoneal carcinoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT02768389 Background | Sep 2016 → Nov 2018 | brain neoplasm, glioblastoma | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 0 | NCT02806817 Background | Jul 2016 → Oct 2018 | Her2-receptor negative breast cancer | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 0 | NCT02802098 Background | May 2016 → Jun 2019 | breast cancer | Spanish National Cancer Research Centre | Completed | No outcome recorded |
| Phase 0 | NCT02457975 Background | Jun 2015 → Aug 2019 | diabetic retinopathy | Medical College of Wisconsin | Completed | No outcome recorded |
| Phase 1116 trials | ||||||
| Phase 1 | NCT07656038 Background | Jun 2026 → Jul 2028 expected | colorectal cancer | STCube, Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07541781 Background | Jun 2026 → Jun 2029 expected | glioblastoma | Kailin Yang, MD, PhD | Recruiting | No outcome recorded |
| Phase 1 | NCT03914768 Background | May 2026 → May 2029 expected | malignant glioma | Shenzhen Geno-Immune Medical Institute | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT07557251 Background | May 2026 → Dec 2028 expected | hepatocellular carcinoma | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07318805 Background | Dec 2025 → Apr 2029 expected | colorectal adenocarcinoma, female breast carcinoma, hormone receptor-positive breast cancer, triple-negative breast carcinoma | Pfizer | Recruiting | No outcome recorded |
| Show all 116 trials opens the full record — a long page | ||||||
| Phase 1/268 trials | ||||||
| Phase 1/2 | NCT07637851 Background | Aug 2026 → Sep 2028 expected | ovarian cancer | ARCAGY/ GINECO GROUP | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07346157 Background | Jul 2026 → Mar 2031 expected | childhood medulloblastoma | Sabine Mueller, MD, PhD | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07551778 Background | May 2026 → Apr 2028 expected | colorectal cancer, non-small cell lung carcinoma | BOE Technology Group Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07391566 Background | Mar 2026 → Dec 2028 expected | colorectal cancer | Luye Pharma Group Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07283367 Background | Dec 2025 → Dec 2029 expected | — | Hansoh BioMedical R&D Company | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06393751 Background | Oct 2025 → Feb 2028 | endometrioid adenocarcinoma, fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube serous adenocarcinoma +6 | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT06294548 Background | Jul 2025 → Jan 2028 expected | hepatocellular carcinoma | University of Alabama at Birmingham | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07079631 Comparator | Jul 2025 → Dec 2030 expected | colorectal cancer | BioNTech SE | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06934538 Background | Jun 2025 → Jun 2028 expected | colorectal cancer | Brenus Pharma | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06873763 Background | Jun → Dec 2025 overdue | colorectal cancer | STCube, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06990516 Background | Jun 2025 → Jun 2030 expected | ovarian cancer | Tongji Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07012954 Comparator | Jun 2025 → Dec 2027 expected | colorectal cancer | Sun Yat-sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06936527 Comparator | May 2025 → Apr 2028 expected | colorectal cancer | NovaOnco Therapeutics Co., Ltd. | Enrolling by invitation | No outcome recorded |
| Phase 1/2 | NCT07204574 Background | May → Dec 2025 overdue | — | Chang Gung Memorial Hospital | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06840002 Background | Mar 2025 → May 2026 overdue | ovarian carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06771622 Background | Mar 2025 → Jan 2028 expected | — | FBD Biologics Limited | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT06703177 Background | Feb 2025 → Jan 2026 overdue | cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06695026 Background | Dec 2024 → Aug 2027 expected | hepatocellular carcinoma | Rznomics, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06584071 Comparator | Dec 2024 → Oct 2026 expected | hepatocellular carcinoma | BioNTech SE | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT06530251 Comparator | Sep 2024 → Jun 2026 overdue | hepatocellular carcinoma | Akeso | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06445062 Background | May 2024 → May 2027 expected | colorectal cancer, pancreatic ductal adenocarcinoma | Revolution Medicines, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06195670 Comparator | Jan 2024 → Jan 2026 overdue | colorectal adenocarcinoma | Zhejiang Cancer Hospital | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05867420 Background | Aug 2023 → Dec 2026 expected | cancer | AskGene Pharma, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05985655 Background | Jul 2023 → Jan 2028 expected | head and neck squamous cell carcinoma, hormone receptor-positive breast cancer, non-small cell lung carcinoma, pancreatic adenocarcinoma +2 | Exscientia AI Limited | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05440708 Background | Mar 2023 → Feb 2027 expected | hepatocellular carcinoma | Tvardi Therapeutics, Incorporated | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05739981 Background | Feb 2023 → Jun 2027 expected | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Imunon | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05609370 Background | Jan 2023 → May 2025 overdue | colorectal cancer | BeiGene | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT05109052 Background | Sep 2022 → Dec 2028 | hepatocellular carcinoma | University of Rochester | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02826837 Background | Sep 2022 → Feb 2024 | colorectal cancer | Taiwan Leader Biotech Corp. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05444088 Background | Aug 2022 → Jun 2026 | hepatocellular carcinoma | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT05405595 Background | Jun 2022 → Oct 2026 expected | — | Adagene Inc | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05337137 Background | May 2022 → Jul 2025 | hepatocellular carcinoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/2 | NCT05083481 Background | Oct 2021 → May 2026 | — | Astellas Pharma Global Development, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT04660812 Background | May 2021 → Sep 2025 | colorectal cancer | Arcus Biosciences, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT04938583 Background | Mar 2021 → Oct 2025 overdue | ovarian carcinoma, uterine adnexa cancer | CanariaBio Inc. | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04689347 Background | Jan 2021 → Apr 2026 overdue | colorectal cancer | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04626635 Background | Dec 2020 → Nov 2026 expected | cancer | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03942328 Background | Sep 2019 → May 2030 expected | hepatocellular carcinoma, intrahepatic cholangiocarcinoma | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04068610 Background | Sep 2019 → Oct 2022 overdue | colorectal cancer | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03829410 Background | Jun 2019 → Jan 2024 | colorectal cancer | Cardiff Oncology | Completed | No outcome recorded |
| Phase 1/2 | NCT03607643 Background | Jan 2019 → Jun 2020 | colon carcinoma, gallbladder cancer, glioblastoma, liver cancer +3 | Leaf Vertical Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT03795311 Background | Nov 2018 → Jan 2023 overdue | colorectal cancer | Centre Georges Francois Leclerc | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03387085 Background | Mar 2018 → Sep 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03127124 Background | Feb 2018 → Dec 2023 | pancreatic adenocarcinoma | NantPharma, LLC | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03167177 Background | Dec 2017 → Jan 2019 | melanoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02866903 Background | May 2017 → Mar 2019 | peritoneal carcinomatosis | Hospices Civils de Lyon | Unknown | No outcome recorded |
| Phase 1/2 | NCT02671435 Background | Feb 2016 → Oct 2021 overdue | cancer | MedImmune LLC | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02244632 Background | Sep 2014 → Jan 2020 | colorectal neoplasm | Isofol Medical AB | Completed | No outcome recorded |
| Phase 1/2 | NCT02078648 Background | May 2014 → Sep 2017 | adult glioblastoma | Stemline Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01996826 Comparator | Apr 2014 → Apr 2019 | corneal neovascularization | Reza Dana, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT01937715 Comparator | Feb 2014 → Aug 2015 | colorectal carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 1/2 | NCT01837862 Background | Oct 2013 → Apr 2024 | anaplastic astrocytoma, diffuse intrinsic pontine glioma, gliosarcoma, optic nerve glioma +2 | Julie Krystal | Completed | No outcome recorded |
| Phase 1/2 | NCT01468831 Background | Mar 2012 → Feb 2020 | occlusion of tributary of retinal vein | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT02118831 Comparator | Mar 2012 → Feb 2014 | age-related macular degeneration, diabetic macular edema, retinal vein occlusion | California Retina Consultants | Completed | No outcome recorded |
| Phase 1/2 | NCT01468844 Background | Dec 2011 → Mar 2015 | retinal vein occlusion | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1/2 | NCT01260506 Background | Dec 2010 → Jul 2015 | glioblastoma | Vascular Biogenics Ltd. operating as VBL Therapeutics | Completed | No outcome recorded |
| Phase 1/2 | NCT01206530 Background | Sep 2010 → Sep 2017 | adenocarcinoma, colon carcinoma, metastatic neoplasm, rectal cancer | Abramson Cancer Center at Penn Medicine | Completed | No outcome recorded |
| Phase 1/2 | NCT01047293 Background | May 2010 → Aug 2015 | colorectal cancer | University of Utah | Completed | No outcome recorded |
| Phase 1/2 | NCT01090830 Background | Apr 2010 → Feb 2012 | non-small cell lung carcinoma | Holy Cross Hospital, Florida | Terminated | No outcome recorded |
| Phase 1/2 | NCT01330524 Comparator | Jan → Nov 2010 | non-arteritic anterior ischemic optic neuropathy | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT01072357 Comparator | Dec 2009 → Jan 2015 | corneal neovascularization | Reza Dana, MD | Completed | No outcome recorded |
| Phase 1/2 | NCT00939991 Background | Oct 2009 → Jan 2012 | brain neoplasm, glioblastoma | Katy Peters | Completed | No outcome recorded |
| Phase 1/2 | NCT00932438 Background | Jun 2009 → Dec 2012 | metastasis from malignant tumor of colon | University of Louisville | Completed | No outcome recorded |
| Phase 1/2 | NCT00745511 Comparator | Mar 2009 → Jun 2010 | macular degeneration | Ora Bio Ltd. | Unknown | No outcome recorded |
| Phase 1/2 | NCT00684996 Comparator | Jun 2008 → Oct 2010 | renal cell carcinoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00784446 Comparator | Apr 2008 → Aug 2010 | colorectal cancer | University of Cologne | Completed | No outcome recorded |
| Phase 1/2 | NCT00625651 Background | Oct 2007 → Aug 2010 | colon carcinoma, rectal carcinoma | Amgen | Completed | No outcome recorded |
| Phase 1/2 | NCT00460603 Comparator | Jan 2006 → Apr 2012 | colorectal neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 2275 trials | ||||||
| Phase 2 | NCT07504588 Background | Sep 2026 → Apr 2029 expected | fallopian tube endometrioid adenocarcinoma, fallopian tube serous adenocarcinoma, ovarian endometrioid adenocarcinoma, primary peritoneal serous adenocarcinoma | National Cancer Institute (NCI) | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07359456 Comparator | Aug 2026 → Aug 2029 expected | colorectal cancer | UNICANCER | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07714668 Background | Aug 2026 → Apr 2028 expected | ovarian cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07663513 Background | Jul 2026 → Apr 2029 expected | ovarian cancer | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07604909 Background | May 2026 → Sep 2027 expected | colorectal cancer | Fudan University | Recruiting | No outcome recorded |
| Show all 275 trials opens the full record — a long page | ||||||
| Phase 2/334 trials | ||||||
| Phase 2/3 | NCT07585279 Background | May 2026 → Feb 2031 expected | colorectal cancer | Hebei Medical University Fourth Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07509398 Background | Apr 2026 → Dec 2027 expected | colorectal cancer | Shanghai 10th People's Hospital | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07472153 Comparator | Jul 2025 → Jun 2030 expected | cervical cancer | N.N. Alexandrov National Cancer Centre | Recruiting | No outcome recorded |
| Phase 2/3 | NCT06755515 Background | Sep 2024 → Sep 2028 expected | cervical cancer | Shandong New Time Pharmaceutical Co., LTD | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT06109272 Comparator | Jan 2024 → Sep 2030 expected | hepatocellular carcinoma | AbbVie | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05976568 Background | Sep 2023 → Sep 2027 expected | hepatocellular carcinoma | Qilu Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT05945901 Comparator | Aug 2023 → Dec 2025 overdue | colorectal cancer | Jiangsu HengRui Medicine Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT05462613 Background | May 2023 → Nov 2029 expected | colorectal cancer | Centre Hospitalier Universitaire de Besancon | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05665348 Background | Mar 2023 → May 2025 | hepatocellular carcinoma, metastatic malignant neoplasm | Federation Francophone de Cancerologie Digestive | Completed | No outcome recorded |
| Phase 2/3 | NCT05582577 Comparator | Oct 2022 → Oct 2023 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT05141721 Background | Feb 2022 → Mar 2027 expected | colorectal neoplasm | Seattle Project Corporation | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT06595355 Background | Oct 2021 → Sep 2025 overdue | diabetic macular edema, macular retinal edema | Isfahan University of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05083689 Comparator | Oct 2021 → Mar 2022 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT04547166 Background | Mar 2021 → Sep 2025 overdue | colorectal cancer | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 2/3 | NCT04511715 Comparator | Sep 2020 → Jan 2021 | diabetic retinopathy | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03821168 Comparator | Mar → Apr 2019 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03609307 Comparator | Sep → Oct 2018 | wet macular degeneration | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03686254 Comparator | Jul 2018 → Oct 2023 | colorectal cancer | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03414983 Background | Feb 2018 → Feb 2021 | colorectal cancer | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2/3 | NCT03391219 Comparator | Jan → Apr 2018 | retinal vein occlusion | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT03353324 Comparator | Nov 2017 → May 2018 | retinal vein occlusion | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT02985619 Comparator | Jul 2016 → Apr 2017 | diabetic macular edema | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2/3 | NCT02414165 Comparator | Nov 2015 → May 2019 | anaplastic astrocytoma, glioblastoma | Tocagen Inc. | Terminated | No outcome recorded |
| Phase 2/3 | NCT02959749 Comparator | Aug 2015 → Oct 2017 | — | Qingdao Central Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT02296567 Comparator | Dec 2014 → Jul 2016 | age-related macular degeneration | East Florida Eye Institute | Unknown | No outcome recorded |
| Phase 2/3 | NCT02901236 Comparator | Jan 2014 → Jan 2015 | glaucoma | Athens Vision Eye Institute | Completed | No outcome recorded |
| Phase 2/3 | NCT01635803 Comparator | Jun 2012 → Jun 2016 | retinal vein occlusion | Academic Medical Center - University of Amsterdam | Unknown | No outcome recorded |
| Phase 2/3 | NCT01635790 Comparator | Jun 2012 → Jun 2016 | diabetic macular edema | Prof. dr. R.O. Schlingemann | Unknown | No outcome recorded |
| Phase 2/3 | NCT01426880 Background | Aug 2011 → May 2013 | HER2 positive breast carcinoma, breast mucinous carcinoma, female breast carcinoma, inflammatory breast carcinoma +1 | GBG Forschungs GmbH | Completed | No outcome recorded |
| Phase 2/3 | NCT01295112 Comparator | May 2011 → Oct 2015 | central retinal vein occlusion | Texas Retina Associates | Completed | No outcome recorded |
| Phase 2/3 | NCT00853073 Comparator | Feb 2009 → Jan 2012 | glaucoma | Wills Eye | Completed | No outcome recorded |
| Phase 2/3 | NCT00555594 Comparator | Sep 2006 | corneal neovascularization | Asociación para Evitar la Ceguera en México | Completed | No outcome recorded |
| Phase 2/3 | NCT00384176 Comparator | Aug 2006 → Nov 2009 | colorectal cancer | AstraZeneca | Completed | No outcome recorded |
| Phase 2/3 | NCT02645734 Comparator | ? → Feb 2016 | diabetic macular edema | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3155 trials | ||||||
| Phase 3 | NCT07271355 Background | Jul 2026 → Feb 2031 expected | appendix carcinoma, peritoneal carcinomatosis | City of Hope Medical Center | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07676162 Background | Jul 2026 → Sep 2029 expected | colorectal cancer | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07286266 Comparator | Jun 2026 → Dec 2029 expected | ovarian neoplasm | GlaxoSmithKline | Recruiting | No outcome recorded |
| Phase 3 | NCT07525206 Background | May 2026 → May 2029 expected | colorectal cancer | AbbVie | Recruiting | No outcome recorded |
| Phase 3 | NCT07225270 Background | Apr 2026 → Oct 2028 expected | ovarian cancer | Genmab | Recruiting | No outcome recorded |
| Show all 155 trials opens the full record — a long page | ||||||
| Phase 429 trials | ||||||
| Phase 4 | NCT07094893 Comparator | Apr 2026 → Mar 2028 expected | colorectal cancer | Gruppo Oncologico del Nord-Ovest | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07358520 Comparator | Jan 2026 → Jan 2027 expected | proteinuria | Fudan University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06850571 Comparator | Feb → Dec 2025 overdue | diabetic retinopathy | Al-Mustansiriyah University | Recruiting | No outcome recorded |
| Phase 4 | NCT06269445 Background | Jan 2024 → Feb 2025 | colorectal cancer | Sir Run Run Shaw Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT06115174 Background | Nov 2023 → Nov 2024 | colorectal carcinoma | Tanta University | Unknown | No outcome recorded |
| Phase 4 | NCT05894694 Background | Sep 2023 → Dec 2025 overdue | colorectal cancer | Guang'anmen Hospital of China Academy of Chinese Medical Sciences | Recruiting | No outcome recorded |
| Phase 4 | NCT07014280 Comparator | Sep 2023 → Sep 2024 overdue | keloid | Kasr El Aini Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT04991350 Comparator | Nov 2021 → Sep 2022 | diabetic macular edema, perifoveal exudative vascular anomalous complex, retinal ischemia | Cairo University | Terminated | No outcome recorded |
| Phase 4 | NCT04674254 Comparator | Mar 2021 → Mar 2023 | perifoveal exudative vascular anomalous complex, proliferative diabetic retinopathy | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03037736 Comparator | Mar 2020 | conjunctival pterygium | University of California, San Francisco | Withdrawn | No outcome recorded |
| Phase 4 | NCT03892434 Comparator | Mar → Dec 2019 | occlusion of tributary of retinal vein | Yeungnam University College of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT05314673 Comparator | Jan 2019 → Jan 2021 | conjunctival pterygium | University Hospital Fattouma Bourguiba | Completed | No outcome recorded |
| Phase 4 | NCT03832179 Comparator | Nov 2018 → Sep 2023 | cataract, diabetic macular edema | Bay Area Retina Associates | Completed | No outcome recorded |
| Phase 4 | NCT05514925 Comparator | Nov 2017 → Nov 2022 | proliferative diabetic retinopathy, retinal detachment | Khairallah Moncef | Unknown | No outcome recorded |
| Phase 4 | NCT03148132 Comparator | May 2017 → Aug 2018 | retinopathy of prematurity | Autonomous University of San Luis Potosí | Completed | No outcome recorded |
| Phase 4 | NCT04619303 Comparator | Feb 2017 → Feb 2020 | diabetic macular edema | Lions Eye Institute, Perth, Western Australia | Completed | No outcome recorded |
| Phase 4 | NCT02594423 Comparator | Dec 2015 → Aug 2017 | corneal neovascularization | University of Nottingham | Unknown | No outcome recorded |
| Phase 4 | NCT02471651 Comparator | Jun 2015 → Oct 2018 | diabetic macular edema | California Retina Consultants | Completed | No outcome recorded |
| Phase 4 | NCT03552770 Comparator | Nov 2014 → Nov 2016 | age-related macular degeneration | University Hospital of Ferrara | Completed | No outcome recorded |
| Phase 4 | NCT02036424 Comparator | Jan 2014 → Aug 2015 | diabetic macular edema | Raj K. Maturi, MD | Completed | No outcome recorded |
| Phase 4 | NCT02015923 Background | Dec 2013 → Jun 2019 | metastasis from malignant tumor of colon | Hospital Universitari de Bellvitge | Terminated | No outcome recorded |
| Phase 4 | NCT01854593 Comparator | May 2012 → Aug 2013 | proliferative diabetic retinopathy, retinal detachment | Nihon University | Completed | No outcome recorded |
| Phase 4 | NCT01309451 Comparator | Mar 2011 → Apr 2013 | diabetic macular edema | Maturi, Raj K., M.D., P.C. | Completed | No outcome recorded |
| Phase 4 | NCT01767545 Comparator | Sep 2010 → Jan 2011 | retinal vein occlusion | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT01085734 Comparator | Mar 2010 → Oct 2011 | retinal vein occlusion | Maturi, Raj K., M.D., P.C. | Completed | No outcome recorded |
| Phase 4 | NCT00737971 Comparator | Aug 2008 → Dec 2012 | diabetic macular edema | Rubens Belfort Jr. | Completed | No outcome recorded |
| Phase 4 | NCT01229202 Comparator | Jul 2008 → Dec 2012 | glaucoma | Nova Scotia Health Authority | Withdrawn | No outcome recorded |
| Phase 4 | NCT00682539 Comparator | Oct 2007 → Jul 2014 | diabetic macular edema | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01025934 Comparator | — | proliferative diabetic retinopathy | University of Campania Luigi Vanvitelli | Completed | No outcome recorded |
| Phase not applicable25 trials | ||||||
| — | NCT07670338 Comparator | Jun 2026 → Sep 2028 expected | pleural disorder | Shanghai Chest Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07466238 Background | Mar 2026 → Mar 2028 expected | biliary tract cancer | Peking University | Recruiting | No outcome recorded |
| — | NCT07338097 Comparator | Sep 2025 → Feb 2026 overdue | diabetic macular edema | CMH Multan Institute of Medical Sciences | Enrolling by invitation | No outcome recorded |
| — | NCT06349044 Background | Mar 2024 → Dec 2025 overdue | biliary tract cancer, colorectal adenocarcinoma, hepatocellular carcinoma | Zhejiang Cancer Hospital | Recruiting | No outcome recorded |
| — | NCT06307080 Background | Oct 2023 → Dec 2025 overdue | malignant pancreatic neoplasm | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Recruiting | No outcome recorded |
| — | NCT05410301 Background | Apr 2023 → Aug 2026 | glioblastoma | Varun Monga, MD | Withdrawn | No outcome recorded |
| — | NCT05284643 Background | Sep 2022 → Sep 2027 expected | glioblastoma | University of Miami | Recruiting | No outcome recorded |
| — | NCT03743428 Comparator | Oct 2020 → Dec 2025 | colorectal neoplasm | Shenzhen People's Hospital | Suspended | No outcome recorded |
| — | NCT04067856 Comparator | Jan 2020 → Jan 2021 | cataract, diabetic macular edema | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Withdrawn | No outcome recorded |
| — | NCT02698254 Comparator | Jul 2016 → Jul 2027 expected | brain neoplasm | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| — | NCT02701231 Background | Nov 2015 → Dec 2020 | lung cancer | Chinese PLA General Hospital | Unknown | No outcome recorded |
| — | NCT02590094 Comparator | Oct 2015 → Jan 2019 | diabetic retinopathy | Panhandle Eye Group, LLP | Completed | No outcome recorded |
| — | NCT02256800 Background | Aug 2014 → Nov 2017 | colorectal cancer | Jaw-Yuan Wang, MD, PhD | Completed | No outcome recorded |
| — | NCT02208128 Comparator | May 2014 → Feb 2018 | renal cell carcinoma | Heidelberg University | Unknown | No outcome recorded |
| — | NCT02076152 Background | Feb 2014 → Apr 2019 | glioblastoma | Massachusetts General Hospital | Completed | No outcome recorded |
| — | NCT01640171 Background | Jul 2012 → Sep 2013 | age-related macular degeneration, central retinal vein occlusion, diabetic macular edema | Retina Vitreous Associates of Florida | Completed | No outcome recorded |
| — | NCT01473251 Comparator | Nov 2011 → Apr 2014 | diabetic macular edema, wet macular degeneration | Vitreo-Retinal Associates, Michigan | Completed | No outcome recorded |
| — | NCT01428388 Comparator | Sep 2011 → Oct 2015 | macular retinal edema, retinal vein occlusion | Barnes Retina Institute | Completed | No outcome recorded |
| — | NCT01256580 Comparator | Aug 2010 → Mar 2013 | angioid streaks, central serous chorioretinopathy, choroidal neovascularization, histoplasmosis retinitis +3 | Massachusetts Eye and Ear Infirmary | Withdrawn | No outcome recorded |
| — | NCT01063283 Comparator | Mar 2010 → Jun 2016 | non-small cell lung carcinoma | University of Chicago | Completed | No outcome recorded |
| — | NCT01141881 Background | May 2009 → Jan 2010 | diabetic macular edema | Mashhad University of Medical Sciences | Terminated | No outcome recorded |
| — | NCT02310295 Comparator | Jan 2009 → Dec 2011 | diabetic macular edema | University of Sao Paulo | Completed | No outcome recorded |
| — | NCT01288404 Comparator | Jan 2008 → Sep 2010 | conjunctival pterygium | Ramathibodi Hospital | Completed | No outcome recorded |
| — | NCT01306591 Comparator | Jan 2008 → Jun 2010 | wet macular degeneration | Peking University People's Hospital | Completed | No outcome recorded |
| — | NCT00802906 Comparator | May 2007 → Nov 2010 | central serous chorioretinopathy | Johann Wolfgang Goethe University Hospital | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT02354612 Background | — | cancer | Tracon Pharmaceuticals Inc. | No longer available | No outcome recorded |
| — | NCT04446793 Background | — | colorectal cancer | Cardiff Oncology | No longer available | No outcome recorded |
Press releases naming this drug 51 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-01-19 | AstraZeneca | Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolisation astrazeneca.com ↗ |
| 2023-11-09 | AstraZeneca | Imfinzi plus bevacizumab met primary endpoint for progression-free survival in liver cancer eligible for embolisation in EMERALD-1 Phase III trial astrazeneca.com ↗ |
| 2023-04-16 | Roche Global Development | Roche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study roche.com ↗ |
| 2023-01-19 | Roche Global Development | [Ad hoc announcement pursuant to Art. 53 LR] Roche’s Tecentriq plus Avastin is the first treatment combination to reduce the risk of cancer returning in people with certain types of early-stage liver cancer in a Phase III trial roche.com ↗ |
| 2022-06-05 | Amgen | NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL CANCER amgen.com ↗ |
| 2021-09-08 | Novartis Pharmaceuticals | Sandoz strengthens pipeline by entering into agreement for biosimilar bevacizumab, a key oncology medicine novartis.com ↗ |
| 2021-05-19 | AbbVie | ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status abbvie.com ↗ |
| 2021-01-12 | Roche Global Development | Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer roche.com ↗ |
| 2020-11-02 | Roche Global Development | European Commission approves Roche’s Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer roche.com ↗ |
| 2020-10-29 | Roche Global Development | Roche’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer roche.com ↗ |
| 2020-09-18 | Roche Global Development | Roche receives positive CHMP opinion for Tecentriq in combination with Avastin for the treatment of people with the most common form of liver cancer roche.com ↗ |
| 2020-09-17 | AbbVie | ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin® at ESMO abbvie.com ↗ |
| 2020-06-02 | Roche Global Development | FDA approves Roche’s Tecentriq in combination with Avastin for people with the most common form of liver cancer roche.com ↗ |
| 2020-05-29 | AbbVie | ImmunoGen Presents Initial Data at ASCO from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status abbvie.com ↗ |
| 2020-05-13 | AbbVie | ImmunoGen Announces Initial Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status abbvie.com ↗ |
| 2020-01-27 | Roche Global Development | Roche submits supplemental Biologics License Application to the FDA for Tecentriq in combination with Avastin for the most common form of liver cancer roche.com ↗ |
| 2019-12-19 | Daiichi Sankyo | Daiichi Sankyo Launches Antitumor Agent Bevacizumab Biosimilar for Intravenous Drip Infusions “Daiichi Sankyo” in Japan daiichisankyo.com ↗ |
| 2019-11-22 | Roche Global Development | Roche presents pivotal data demonstrating Tecentriq in combination with Avastin improves overall survival in people with the most common form of liver cancer roche.com ↗ |
| 2019-10-21 | Roche Global Development | Roche’s Tecentriq in combination with Avastin increased overall survival and progression-free survival in people with unresectable hepatocellular carcinoma roche.com ↗ |
| 2019-09-29 | AbbVie | ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin® at ESMO abbvie.com ↗ |
| 2019-09-27 | Roche Global Development | Roche’s Tecentriq in combination with Avastin shows encouraging results in Phase Ib study of people with unresectable hepatocellular carcinoma roche.com ↗ |
| 2019-07-19 | Amgen | Amgen And Allergan's MVASI™ (bevacizumab-awwb) And KANJINTI™ (trastuzumab-anns) Now Available In The United States amgen.com ↗ |
| 2019-06-28 | Pfizer | Pfizer Receives U.S. FDA Approval for Its Oncology Biosimilar, ZIRABEV™ (bevacizumab-bvzr) pfizer.com ↗ |
| 2019-06-02 | Roche Global Development | Roche’s Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer shows positive data in those with liver metastases roche.com ↗ |
| 2019-05-15 | AbbVie | ImmunoGen Announces Mature Data from FORWARD II Expansion Cohort Evaluating Mirvetuximab Soravtansine in Combination with Avastin® in Ovarian Cancer abbvie.com ↗ |
| 2019-03-08 | Roche Global Development | European Commission approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer roche.com ↗ |
| 2019-02-19 | Pfizer | Pfizer Receives European Approval for ZIRABEV™ (bevacizumab), a Biosimilar to Avastin®* pfizer.com ↗ |
| 2019-02-01 | Roche Global Development | CHMP recommends EU approval of Roche's Tecentriq in combination with Avastin and chemotherapy as an initial treatment for lung cancer roche.com ↗ |
| 2018-12-14 | Pfizer | Pfizer Receives Positive CHMP Opinion for Oncology Biosimilar, ZIRABEV™ (bevacizumab) pfizer.com ↗ |
| 2018-12-07 | Roche Global Development | FDA approves Roche's Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer roche.com ↗ |
| 2018-07-18 | Roche Global Development | FDA grants Breakthrough Therapy Designation for Roche's Tecentriq in combination with Avastin as first-line treatment for advanced or metastatic hepatocellular carcinoma (HCC) roche.com ↗ |
| 2018-06-13 | Roche Global Development | FDA approves Roche’s Avastin (bevacizumab) plus chemotherapy as a treatment for women with advanced ovarian cancer following initial surgery roche.com ↗ |
| 2018-05-17 | Roche Global Development | Phase III IMpower150 study showed Roche’s Tecentriq and Avastin plus carboplatin and paclitaxel helped people with a specific type of metastatic lung cancer live significantly longer compared to Avastin plus carboplatin and paclitaxel roche.com ↗ |
| 2018-05-16 | AbbVie | ImmunoGen Announces Positive Findings from the FORWARD II Study of Mirvetuximab Soravtansine Combination Regimens with Avastin® and Carboplatin in Ovarian Cancer abbvie.com ↗ |
| 2018-03-26 | Roche Global Development | Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus carboplatin and paclitaxel helped people with advanced lung cancer live longer compared to Avastin plus carboplatin and paclitaxel roche.com ↗ |
| 2018-02-06 | Roche Global Development | Phase III IMmotion151 study showed Roche's TECENTRIQ® (atezolizumab) and Avastin® (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer roche.com ↗ |
| 2018-01-18 | Amgen | European Commission Approves Amgen And Allergan's MVASI® (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer amgen.com ↗ |
| 2017-12-11 | Roche Global Development | Phase III IMmotion151 study showed Roche’s Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death for the initial treatment of certain people with advanced kidney cancer roche.com ↗ |
| 2017-12-07 | Roche Global Development | Phase III IMpower150 study showed Tecentriq (atezolizumab) and Avastin (bevacizumab) plus chemotherapy reduced the risk of disease worsening or death by 38 percent for people with a type of advanced lung cancer roche.com ↗ |
| 2017-11-20 | Roche Global Development | Phase III IMpower150 study showed Roche’s TECENTRIQ (atezolizumab) and Avastin (bevacizumab) plus chemotherapy significantly reduced the risk of disease worsening or death in the initial treatment of people with a type of advanced lung cancer roche.com ↗ |
| 2017-11-10 | Amgen | Amgen And Allergan Receive Positive CHMP Opinion For ABP 215 (Biosimilar Bevacizumab) For The Treatment Of Certain Types Of Cancer amgen.com ↗ |
| 2017-09-14 | Amgen | FDA Approves Amgen And Allergan's MVASI™ (bevacizumab-awwb) For The Treatment Of Five Types Of Cancer amgen.com ↗ |
| 2017-07-24 | Pfizer | Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (bevacizumab) pfizer.com ↗ |
| 2017-07-13 | Amgen | Amgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate To Avastin® (bevacizumab) amgen.com ↗ |
| 2017-06-07 | Amgen | Amgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab amgen.com ↗ |
| 2017-02-18 | Roche Global Development | Phase II study supports potential for Roche’s TECENTRIQ (atezolizumab) plus Avastin (bevacizumab) for people with locally advanced or metastatic renal cell carcinoma roche.com ↗ |
| 2016-12-07 | Roche Global Development | Roche’s Avastin (bevacizumab) plus chemotherapy receives FDA approval for platinum-sensitive recurrent ovarian cancer roche.com ↗ |
| 2016-12-02 | Amgen | Amgen And Allergan Submit Biosimilar Marketing Authorization Application To European Medicines Agency For ABP 215, A Biosimilar Candidate To Bevacizumab amgen.com ↗ |
| 2016-10-10 | Amgen | New Retrospective Analyses Confirm Vectibix® (Panitumumab) Treatment Provided Survival Benefit Over Chemotherapy With Or Without Bevacizumab In Metastatic Colorectal Cancer Patients With Tumors Of Left-Sided Origin amgen.com ↗ |
| 2016-06-08 | Roche Global Development | Roche receives EU approval of Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer roche.com ↗ |
| 2016-04-29 | Roche Global Development | CHMP recommends EU approval for Roche's Avastin in combination with Tarceva for patients with a specific type of advanced lung cancer roche.com ↗ |
Evidence & citations 63 cited values
Every value below carries the sentence it was read from. 2,760 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | bevacizumab | “This study is to prove that the handling (also referred to as pharmacokinetics) of the following drugs PF-06439535, Avastin® (bevacizumab) that is licensed for use in the...” NCT02031991 ↗2620“Investigator's choice of standard first-line systemic therapy for initially unresectable colorectal cancer, including chemotherapy (e.g., FOLFOX, FOLFIRI, CAPOX) with or...” NCT07509398 ↗ “EO2401 is an innovative cancer peptide therapeutic vaccine based on the homologies between Tumor Associated Antigens and microbiome-derived peptides that will be administered...” NCT04116658 ↗ “Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used...” NCT02457975 ↗ “The vascular endothelial growth factor pathway is biologically important in pancreatic cancer, and docetaxel has modest antitumor activity. We evaluated the role of the...” PMID 20458210 ↗ Feb 2011 “Fudan CUP-002 study (ClinicalTrials.gov identifier: NCT04848597), an investigator-initiated prospective trial, was designed to evaluate the efficacy and safety of an anti-PD-1...” PMID 42103741 ↗ May 2026 “Treatment-naïve NSCLC patients with brain metastasis harboring EGFR-activating mutations were treated with osimertinib 80 mg oral daily and bevacizumab 15 mg/kg intravenously...” PMID 37016906 ↗ Apr 2023 “Drug sensitivity testing will be performed on a panel of approved targeted and immunotherapeutic agents (including Apatinib, Atezolizumab + Bevacizumab, Donafenib +...” NCT07363356 ↗ “Another recent trial in patients with advanced HCC demonstrated improved survival with the combination of Atezolizumab, an immune checkpoint inhibitor (ICI), and Bevacizumab,...” NCT05137899 ↗ “Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Oxaliplatin 130mg/m2+Capecitabine 1250mg/m2 for 6-8cycles, Sintilimab 200mg+ Bevacizumab 7.5mg/kg+Capecitabine 1250mg/m2 as maintenance...” NCT06973343 ↗ “Sintilimab will be administered at 200 mg i.v. every 3 weeks plus a bevacizumab biosimilar at 15 mg/kg i.v. every 3 weeks until documented disease progression, development of...” NCT04954794 ↗ “The intervention consists of furmonertinib (240 mg/d, po) combined with bevacizumab (15 mg/kg, every 3 weeks, ivgtt) and pemetrexed (50 mg) intrathecal chemotherapy /...” NCT06643000 ↗ “In total, 136 patients will be randomized in a 2:1 ratio to [177Lu]Lu-DOTATATE (≤4 doses of 7.4 GBq given every 4 wk) or local standard of care (hydroxyurea, bevacizumab,...” PMID 40774695 ↗ Jan 2026 “The FDA has also approved the use of a drug called bevacizumab (or Avastin) in combination with FOLFIRI, and this is considered one of the standards of care for all patients...” NCT01183494 ↗ “combinations such as atezolizumab plus bevacizumab, tremelimumab plus durvalumab, or monotherapies such as lenvatinib, sorafenib, tislelizumab, durvalumab, or pembrolizumab, at...” NCT06841172 ↗ “Patients with mCRC were randomized to arfolitixorin (120 mg/m2 given as two intravenous bolus doses of 60 mg/m2) or leucovorin (400 mg/m2 given as a single intravenous...” PMID 38059497 ↗ Jan 2024 “Drug: Bevacizumab 15mg/kg IV of EU-approved Avastin will be administered every 3 weeks up to 6 cycles during the Induction Study Period and every 3 weeks until PD or...” NCT03676192 ↗ “PURPOSE: To investigate the comparative efficacy of bevacizumab (Avastin) and ranibizumab (Lucentis; both Genentech, Inc, South San Francisco, CA) for diabetic macular edema...” PMID 26875003 ↗ Feb 2016 “The purpose of this study is to determine the efficacy and safety of intravitreal injections of bevacizumab in High Myopia´s choroidal neovascularization versus the standard...” NCT00967850 ↗ “1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and...” NCT00776763 ↗ “The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until...” NCT02701231 ↗ “furmonertinib (160mg, once a day, continuous administration); bevacizumab (7.5 mg/kg body weight, once every 3 weeks); Pemetrexed (50 mg intrathecal injection chemotherapy,...” NCT06812871 ↗ “Physician's Choice of carboplatin (preferred) or cisplatin，gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin，with or without bevacizumab.” NCT05684731 ↗ “Participants will receive selected SoC regimen (fulvestrant, paclitaxel + bevacizumab, pegylated liposomal doxorubicin, or capecitabine) administered as specified in the treatment arm.” NCT05985655 ↗ “Induction therapy was sintilimab 200mg IV d1, bevacizumab 7.5mg/kg IV d1, albumin-bound paclitaxel 260mg/m2 IV d1 and cisplatin 80mg/m2 IV d1, once every 3 weeks, a total of 3 cycles.” NCT06752382 ↗ “Determine the time to progression for the combination of erlotinib and bevacizumab in patients with previously treated metastatic cancer of the esophagus or gastroesophageal junction” NCT00442507 ↗ “The treatment option for the chidamide + sintilimab + bevacizumab (study group) is 200 mg of sintilimab IV Drip Q3W, 30 mg of chidamide PO BIW, and bevacizumab 7.5 mg/kg IV Drip Q3W” NCT05768503 ↗ “The patient will receive intravenous cyclophosphamide (200 mg/m2) or oral (cytoxan) before the vaccine, followed by DC vaccine and intravenous bevacizumab (15 mg/kg) the next day.” NCT03914768 ↗ “The purpose of this study is to investigate the safety and efficacy of intravitreal bevacizumab in patients with choroidal neovascularization associated with angioid streaks.” NCT00406250 ↗ “Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.” NCT01439178 ↗ “First-line standard systemic therapies in cohort A include: FOLFOX/FOLIRI/XELOX+ bevacizumab, FOLFOX/FOLIRI/XELOX+cetuximab (KRAS/NRAS/BRAF WT and left-sided tumors only).” NCT06841159 ↗ “The neoadjuvant regimen prior to radiotherapy consists of albumin-bound paclitaxel/pemetrexed, cisplatin, Bevacizumab, iparomlimab and tuvonralimab, and thymosin alpha 1.” NCT07103395 ↗ “Patients in arm B will receive maximum 4 cycles of CAPOX or 6 cycles of FOLFOX/FOLFIRI +/- bevacizumab regardless of the location of primary tumor or RAS/BRAF mutation.” NCT05861505 ↗ “hydroxychloroquine 200 mg TID PO+ methotrexate 2.5 mg BID twice a week PO+ capecitabine 1000 mg/m2 PO BID for 14 days+ bevacizumab 7.5 mg/m2 IV on day 1, every 3 weeks.” NCT06949982 ↗ “STC-1010 administered with immunostimulants (IS) in low-dose (cyclophosphamide and GM-CSF) and standard of care (SOC) therapy (mFOLFOX6 with or without bevacizumab)” NCT06934538 ↗ “Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.” NCT01322815 ↗ “Patients will receive node-sparing modified short-course radiotherapy, followed by 8 cycles of FOLFOX chemotherapy combined with bevacizumab and a PD-1 inhibitor.” NCT06958419 ↗ “Subjects who met the conditions of the study population were treated with Cadonilimab 10mg/kg + bevacizumab 7.5 mg/kg + carboplatin (AUC 5) + pemetrexed 500mg/m2.” NCT05812534 ↗ “Bevacizumab (15mg/kg) is a vascular endothelial growth factor inhibitor given in 21-day cycles over six months in combination with Memantine and Atezolizumab.” NCT06789757 ↗ “Bevacizumab, a recombinant humanized monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), has clinical activity in multiple tumor types.” PMID 21537039 ↗ May 2011 “Chemotherapy regimen with either mFOLFOX6 plus cetuximab, bevacizumab or mFOLFOX6 alone were allocated, according the RAS genotype and patient affordability.” NCT01307878 ↗ “National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab” NCT03142282 ↗ “Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.” PMID 26186012 ↗ Jul 2015 “A Randomized, Open-Label Trial Comparing Two Avastin (Bevacizumab)-Based Treatment Regimens for the First-Line Treatment of Metastatic Colorectal Cancer” NCT00114946 ↗ “10 mg/kg bevacizumab i.v. (days 1 and 15, q4w) plus either 50 mg/m2 docetaxel (days 1 and 15, q4w) or 90 mg/m2 paclitaxel (days 1,8 and 15, q4w) i.v.” PMID 27919965 ↗ Dec 2016 “Bevacizumab, which will be given through a vein over 30 to 90 minutes on the first day of each 21-day cycle following the infusion of docetaxel” NCT00942578 ↗ “In the Sin-Bev-TACE arm, sintilimab (200mg I.V. q3w) and bevacizumab (7.5mg/kg I.V. q3w) will be started at 3-7 days after the first TACE.” NCT05985798 ↗ “XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks” NCT00335595 ↗ “The aim of this study is to determine the safety and efficacy of intravitreal bevacizumab in the treatment of retinopathy of prematurity” NCT00346814 ↗ “The specific regimen is: Paclitaxel(135mg/m2,ivd, d1)+cisplatin(75mg/m2,ivd,d1-3)+Toripalimab (240mg,ivd,d1)±bevacizumab(ivd, d1)/q21d.” NCT06093438 ↗ “Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)” NCT04812977 ↗ “Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.” NCT05601973 ↗ “Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)” NCT00254319 ↗ “Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles” NCT02185352 ↗ “afatinib 40mg oral, bevacizumab 15mg/kg iv, every 21days, until progression disease, untolerated toxicities, or patient death.” NCT05267288 ↗ “Or continue the two-week regimen of albumin paclitaxel+bevacizumab for 3 cycles, while PD-1 monoclonal antibody for 2 cycles.” NCT06371586 ↗ “Platinum-based standard of care doublet chemotherapy (or triplet if bevacizumab is used) will be given by IV every 3 weeks.” NCT03977467 ↗ “mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment” NCT03135652 ↗ “bevacizumab (Onbevzi) at a dose of 15 mg/kg administered as a 30-minute intravenous infusion on Day 1 of each 21-day cycle” NCT07547592 ↗ “Atezolizumab (1200mg) and Bevacizumab (15mg/kg) are administered to patients once for each cycle with 3-week intervals” NCT05908916 ↗ “To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema” NCT00371111 ↗ “A Phase II Trial of Neoadjuvant Bevacizumab, Docetaxel and Carboplatin for Triple Negative Breast Cancer (Neat Trial)” NCT01208480 ↗ “Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence” NCT01526837 ↗ “Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer” NCT01661790 ↗ “Antiangiogenesis targeted drugs: Bevacizumab or Anlotinib Hydrochloride, according to the standard dose treatment.” NCT06878625 ↗ “6 courses of platinum/etoposide/bevacizumab/camrelizumab and a total period of 12 months bevacizumab/camrelizumab” NCT04635956 ↗ “All patients were treated with 1.25 mg of intravitreal bevacizumab followed by RF-PDT (25 J/cm²), 2 days later.” NCT00802126 ↗ “adding vascular endothelial growth factor (VEGF) monoclonal antibody, Bevacizumab, to standard neoadjuvant CCRT” NCT02812641 ↗ “BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1” NCT01071655 ↗ “Combination treatment may include: 5FU/LFA, capecitabine, oxaliplatin, irinotecan, bevacizumab, aflibercept” NCT07213570 ↗ “BEV(bevacizumab) at 15 mg/kg, administered by intravenous infusion on Day 1, with a 3-week treatment cycle.” NCT07669610 ↗ “Paclitaxel (175mg/m2), carboplatin (AUC 5.0 or 6.0) IV, and bevacizumab IV (15mg/kg) D1, every three weeks.” NCT04201561 ↗ “three intravitreal injections of bevacizumab (Avastin) 2.5 mg versus a sham procedure for treatment of NVG” NCT00384631 ↗ “QL1706 5mg/kg q3w + bevacizumab 7.5mg/kg q3w group and QL1706 5mg/kg q3w + bevacizumab 15mg/kg q3w group” NCT05603039 ↗ “Safety of Atezolizumab-Bevacizumab in Liver Transplanted Patients With Advanced Hepatocellular Carcinoma” NCT06254248 ↗ “Osimertinib, 80mg, oral daily; bevacizumab (avastin), 15mg/KG body weight, erery 21 days, intravenously.” NCT04974879 ↗ “FDA approved drugs for the study population: Bevacizumab, Docetaxel, Erlotinib, Gemcitabine, Pemetrexed” NCT02045446 ↗ “for patients who received bevacizumab combined with atezolizumab/sintilimab as the first-line treatment” NCT06592612 ↗ “D1: VEGFR bevacizumab 10mg/kg d1,15 ivgtt + nab-paclitaxel 100mg/m2 d1,8,15 ivgtt, 4 weeks as a cycle.” NCT04395989 ↗ “Bevacizumab is a biologic antibody approved in many countries for the treatment of metastatic CRC.” PMID 34014555 ↗ May 2021 “Tilelizumab combined with XELOX and bevacizumab or tislelizumab combined with FOLFOX and cetuximab” NCT05409417 ↗ “Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)” NCT00511992 ↗ “Standard second-line systemic therapy: (XELOX/FOLFOX or XELIRI/FOLFIRI ± bevacizumab/cetuximab)” NCT07079462 ↗ “Bevacizumab given at 7.5mg/kg. IV over 10-90 minutes every 3 weeks until disease progression.” NCT01057017 ↗ “Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months.” NCT00970957 ↗ “+/- bevacizumab 7.5 milligrams per kilograms (mg/kg) every 21 days or 15 mg/kg every 21 days” NCT03602859 ↗ “KRAS/NRAS Mutant or Right-Sided Tumor: Bevacizumab (5 mg/kg IV over 30-90 minutes, Day 1).” NCT06575127 ↗ “Targeted Therapy: Bevacizumab 7.5-10 mg/kg, once every 3 weeks, for a total of 4-6 courses” NCT06999148 ↗ “TQB2930 injection + Oxaliplatin injection + Capecitabine tablets + Bevacizumab injection” NCT07653685 ↗ “Regorafenib. Fruquintinib. Trifluridine/Tipiracil (TAS-102) with or without Bevacizumab.” NCT07353268 ↗ “combination of cetuximab/bevacizumab and other targeted agents depends on the patient.” NCT05797883 ↗ “Atezilizumab combined with bevacizumab used outside of indication, based on biomarkers” NCT04817956 ↗ “Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months” NCT01015300 ↗ “Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF)” NCT03780010 ↗ “atezolizumab+bevacizumab, camrelizumab+apatinib, sintilimab+bevacizumab and so on” NCT04135690 ↗ “Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients).” NCT01426880 ↗ “combine or not combine with Bevacizumab or Cetuximab; every 14 days for a cycle.” NCT03567629 ↗ “Bevacizumab: 7.5 mg/kg, intravenous infusion, 1 day, 3 weeks as one study cycle” NCT07457775 ↗ “Treatment With ORA102 Combined With Avastin (Bevacizumab) Versus Avastin Alone” NCT00745511 ↗ “Bevacizumab is an antiangiogenic use in the treatment of colorectal cancers .” NCT02157987 ↗ “SIBP04 is a biosimilar of bevacizumab (Avastin®, Roche, Basel, Switzerland).” PMID 40697509 ↗ Jan 2025 “Bevacizumab will be administered by IV infusion at a fixed dose of 15 mg/kg” NCT04712643 ↗ “Bevacizumab 5 mg/kg, intravenous infusion, Day 1, repeated every 2 weeks” NCT07604909 ↗ “Investigator's Choice Treatment：bevacizumab, temozolomide or hydroxyurea” NCT07613450 ↗ “Drug: bevacizumab 5mg/kg given by IV every 14 days. Other Name: Avastin” NCT05652894 ↗ “Radiotherapy followed by Adebrelimab+Bevacizumab+Cisplatin/Carboplatin” NCT07638852 ↗ “Drug: Bevacizumab 5mg/kg, intravenous infusion, d1, 14 days per cycle.” NCT07309289 ↗ “intravitreal bevacizumab (IVB) group with four monthly IVB injections” PMID 35594075 ↗ Jun 2022 “Bevacizumab: 7.5 mg/kg via intravenous infusion every 3 weeks (Q3W).” NCT06858969 ↗ “K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks.” NCT01366118 ↗ “bevacizumab: 7.5 mg/kg, intravenously infused before HAIC treatment” NCT06739252 ↗ “Bevacizumab : 7.5 mg / kg (with a maximum of 750 mg) on day 1 (D1)” NCT04822818 ↗ “Atezolizumab/Bevacizumab in Subjects With Hepatocellular Carcinoma” NCT06695026 ↗ “Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC” NCT06397222 ↗ “weekly paclitaxel and bevacizumab with or without zoledronic acid” NCT05053750 ↗ “first-line regimen (FOLFOX/FOLFIRI/CAPEOX± Cetuximab/bevacizumab)” NCT05894694 ↗ “Bevacizumab (Avastin) is a humanized monoclonal antibody to VEGF.” NCT00888043 ↗ “proposed bevacizumab biosimilar HLX04 with reference bevacizumab” PMID 34086067 ↗ Jun 2021 “Bevacizumab®, 5 mg/kg IV every 14 days with mFOLFOX6 for 1 cycle” NCT05378867 ↗ “First line fluoropyrimidine-based chemotherapy with bevacizumab.” NCT01606098 ↗ “Bevacizumab: 10 mg/kg for up to 8 cycles from date of first dose” NCT01985841 ↗ “Bevacizumab (Bevacizumab™)- Rituximab (Rituxan®)-CHOP (RA-CHOP)” NCT00401817 ↗ “This injection may be ranibizumab, bevacizumab, or aflibercept.” NCT02471651 ↗ “Sintilimab plus bevacizumab plus platinum-doublet chemotherapy” NCT06775743 ↗ “bevacizumab 7.5 mg/kg IV infusion on Day 1, q3w, for 5 cycles” NCT07581626 ↗ “Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8” NCT00830544 ↗ “bevacizumab 15 mg/kg beginning on cycle 2 and PLD 30 mg/m(2)” PMID 22851407 ↗ Jul 2012 “followed by toripalimab of 240mg plus bevacizumab (15mg/kg)” NCT07380633 ↗ “Bevacizumab: intravenous infusion, 7.5mg/kg, on day 1, q3w.” NCT06195670 ↗ “EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)” NCT02453672 ↗ “Bevacizumab + Atezolizumab 1200mg 6 weekly (up to 2 years)” NCT06422403 ↗ “Bevacizumab intravenously at dose 10mg/kg every other wk.” NCT00613028 ↗ “six cycles of platinum-based chemotherapy +/- bevacizumab” NCT05704621 ↗ “Drug:Bevacizumab Injection Q2W Administered intravenously” NCT07387081 ↗ “Bevacizumab 1.25 mg / 0.05mL for intravitreal injection.” NCT07429474 ↗ “a bevacizumab biosimilar (15 mg/kg intravenous infusion)” NCT06031285 ↗ “paclitaxel+cisplatin/carboplatin ± bevacizumab+QL1706” NCT07035808 ↗ “Carboplatin + Pemetrexed + Bevacizumab + Atezolizumab” NCT03786692 ↗ “K-ras native: Cetuximab. K-ras mutated: Bevacizumab” NCT01453257 ↗ “Sintilimab 200mg d1 and Bevacizumab 15mg/kg d1 q21d” NCT04213170 ↗ “with or without bevacizumab 5mg/kg, every 2 weeks” NCT02969681 ↗ “Bevacizumab in combination with Interfereon-alfa” NCT01731158 ↗ “bevacizumab (15 mg/kg intravenous infusion, q3w)” NCT07522411 ↗ “Drug: Bevacizumab administered as an IV infusion” NCT05765032 ↗ “every 2 weeks with or without bevacizumab 5mg/kg” NCT04516681 ↗ “Bevacizumab for tumors harboring KRAS mutations” NCT06555003 ↗ “Drug: Bevacizumab (15 mg/kg, IV, every 3 weeks)” NCT07062055 ↗ “* Bevacizumab 5 mg/kg IV over 90 mins on Day 1” NCT01923987 ↗ “Intravitreal injection of 1.25 mg bevacizumab” NCT00797992 ↗ “±bevacizumab 7.5mg/kg, intravenous, on day 1” NCT03485027 ↗ “Bevacizumab (7.5mg/kg IV infusion, D1, Q3w)” NCT07198165 ↗ “Bevacizumab 15mg/kg ivgtt once every 21day” NCT05266846 ↗ “avastin,bevacizumab, eylea, aflibercept,” NCT02357342 ↗ “cetuximab 250mg/m2 or bevacizumab 5mg/kg” NCT03022734 ↗ “Avastin (Bevacizumab) and triamcinolone” NCT00370630 ↗ “Bevacizumab (15mg/kg) i.v. day 1 q 22” NCT01200212 ↗ “bevacizumab (15 mg/kg, every 3 weeks)” NCT06971406 ↗ “Intravitreal injection of bevacizumab” NCT01716026 ↗ “Drug:Bevacizumab Intravenous Infusion” NCT05179317 ↗ “VEGFR bevacizumab 10mg/kg d1,15 ivgtt” NCT05806060 ↗ “infusional 5-FU, LV, and bevacizumab” NCT05329103 ↗ “bevacizumab and paclitaxel induction” PMID 42128502 ↗ May 2026 “Bevacizumab 7.5 mg/kg every 3 weeks” NCT07130032 ↗ “CETUXIMAX / BEVACIZUMAB/PANITUMUMAB” NCT02015923 ↗ “Bevacizumab (BEV): 5mg/kg (d.i.v.);” NCT04160416 ↗ “bevacizumab (5 mg/kg, iv drop, d1)” NCT07515963 ↗ “MRG006A+Pucotenlimab + Bevacizumab” NCT07479485 ↗ “Bevacizumab, 15mg/kg, iv drip, q3w” NCT07501351 ↗ “reference bevacizumab (Avastin®)” PMID 34269848 ↗ Jul 2021 “Bevacizumab: 5 mg/kg IV on Day 1” NCT06521866 ↗ “bevacizumab (7.5 mg/kg, Q3W, D1)” NCT07446387 ↗ “Bevacizumab 15 mg/kg ivdrip, Q3W” NCT05400902 ↗ “Biological: bevacizumab Given IV” NCT03641976 ↗ “Dalutin ® Bevacizumab 15mg/kg IV” NCT06590844 ↗ “Bevacizumab: 7.5 mg/kg, D1, Q3W” NCT07347444 ↗ “Bevacizumab: 15 mg/kg Q3 W, iv.” NCT06509971 ↗ “bevacizumab (7.5 mg/kg, days1)” NCT07416058 ↗ “mFOLFOX6+ HLX04 (bevacizumab).” NCT06491355 ↗ “target therapy (Bevacizumab).” NCT06115174 ↗ “Bevacizumab 15mg/kg d1 iv q3w” NCT06349044 ↗ “bevacizumab (5 mg/kg; day 1)” NCT06242067 ↗ “Bevacizumab: 15mg/kg d1, IV” NCT01941407 ↗ “bevacizumab 5 mg/kg IV q3w” NCT06145308 ↗ “bevacizumab mg/kg IV day 1” NCT05353582 ↗ “Anti-VEGF IV (bevacizumab)” NCT04171141 ↗ “FOLFOX/XELOX+ bevacizumab” NCT06525428 ↗ “Biological: Bevacizumab” NCT06241235 ↗ “Bevacizumab (Avastin®)” NCT03390673 ↗ “Avastin (bevacizumab)” NCT00109057 ↗ “Avastin (bevacizumab)” NCT00096967 ↗ “Avastin (Bevacizumab)” NCT00336648 ↗ “Avastin (bevacizumab)” NCT00557492 ↗ “Bevacizumab (Avastin)” NCT03585556 ↗ “4. VEGFA: Bevacizumab” NCT02101385 ↗ “Bevacizumab (Avastin)” NCT02348359 ↗ “Bevacizumab (Avastin)” NCT00635050 ↗ “Drug: Bevacizumab” NCT03872947 ↗ “Drug: Bevacizumab” NCT04988607 ↗ “Drug: Bevacizumab” NCT07179900 ↗ “Drug: Bevacizumab” NCT00804830 ↗ “Drug: Bevacizumab” NCT02641873 ↗ “Drug: Bevacizumab” NCT06060704 ↗ “Drug: Bevacizumab” NCT00923936 ↗ “Drug: Bevacizumab” NCT03635021 ↗ “* Bevacizumab” NCT03251612 ↗ “Bevacizumab” NCT05739981 ↗ “Bevacizumab” NCT04355858 ↗ “bevacizumab” NCT03630315 ↗ |
| Known as | albumin binding paclitaxel | “carreilizumab 200 mg IV D1+ gemcitabine 1000mg/㎡ IV+ albumin binding paclitaxel 125mg/㎡ IV D1.8Q3W; For 6 weeks” NCT06307080 ↗ |
| Known as | Altuzan | “Bevacizumab (Altuzan) was injected subconjunctival space of the patients.” NCT02796183 ↗ |
| Known as | Anda | “Bevacizumab (Anda, Qilu Pharmaceutical): 5 mg/kg, repeated every 2 weeks, administered by intravenous drip (ivgtt).” NCT05364489 ↗ |
| Known as | Avastin | “Threeintravitreous VEGF inhibitors - aflibercept (Eylea, Regeneron Pharmaceuticals), bevacizumab (Avastin, Genentech), and ranibizumab (Lucentis, Genentech) - are commonly used...” NCT02457975 ↗281“The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two...” NCT03919448 ↗ “Terence M. Davidson, MD is conducting a research study to find out more about the topical application of Avastin (proper chemical name is bevacizumab) in the treatment of...” NCT01397695 ↗ “Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous...” PMID 34184418 ↗ Jun 2021 “In clinic, recent studies showed a significant benefit of bevacizumab (Avastin®) in the treatment of primary brain tumors, as shown by Vredenburgh et al. for patients with...” NCT01332929 ↗ “The FDA has also approved the use of a drug called bevacizumab (or Avastin) in combination with FOLFIRI, and this is considered one of the standards of care for all patients...” NCT01183494 ↗ “The purpose of this study is to evaluate the objective response rate of a combination of letrozole (Femara) and bevacizumab (Avastin) given preoperatively to postmenopausal...” NCT00461773 ↗ “Bevacizumab (Avastin®): 5 mg/kg IV infusion in 100 mL of 0.9% saline over 90 minutes for the first infusion, then 60 minutes for the second infusion if tolerated, and 30...” NCT00467142 ↗ “The purpose of this study is to determine whether combination therapy with bevacizumab (Avastin), dacarbazine and interferon-alfa-2a (Roferon-A) is effective in patients with...” NCT00308607 ↗ “A 24 Month Phase 2A Open Label Safety Study of Fovista® (Anti-PDGF-BB Pegylated Aptamer) Regiment Administered in Combination With Avastin®, Eylea®, or Lucentis®) During the...” NCT02214628 ↗ “Preoperative administration of bevacizumab (Avastin; Genentech, Inc, South San Francisco, California, USA), a full-length recombinant humanized monoclonal antibody targeting...” NCT02590094 ↗ “The AVEREL trial [A Study of Avastin (Bevacizumab) in Combination With Herceptin (Trastuzumab)/Docetaxel in Patients With HER2-Positive Metastatic Breast Cancer] evaluated...” PMID 23569311 ↗ Apr 2013 “This is a research study to find out more about the use of Avastin (proper chemical name is bevacizumab) in the treatment of epistaxis (nose bleeding) in patients with...” NCT01402531 ↗ “PURPOSE: To investigate the comparative efficacy of bevacizumab (Avastin) and ranibizumab (Lucentis; both Genentech, Inc, South San Francisco, CA) for diabetic macular edema...” PMID 26875003 ↗ Feb 2016 “Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor (bevacizumab) is Avastin produced by Zhengda Tianqing Pharmaceutical Group...” NCT05476341 ↗ “1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and...” NCT00776763 ↗ “Participants received bevacizumab (Avastin) 5 mg/kg intravenous (iv) on day 1 of each 2 week cycle plus erlotinib (Tarceva) 150 mg orally once a day until disease progression...” NCT00605722 ↗ “Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (5mg/kg) followed by chemotherapy of mFOLFOX6 until progressive disease or...” NCT01972490 ↗ “Bevacizumab (Avastin, Genentech, Inc.) is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), which has been used to treat a variety of...” NCT00673296 ↗ “Currently there is one additional anti-VEGF drug already on the market: Bevacizumab (Avastin™), which has approved as intravenous infusion for the treatment of metastatic...” NCT00545870 ↗ “Efficacy and Safety of Bevacizumab (Avastin®) Combined to Weekly Paclitaxel Followed by Bevacizumab (Avastin®) Alone in Patients With Relapsed Ovarian Sex-cord Stromal Tumours (ALIENOR)” NCT01770301 ↗ “This is a randomized, controlled, double-blind, placebo-controlled trial of intranasal Avastin (bevacizumab) injection versus saline control for control of HHT-related epistaxis” NCT02389959 ↗ “Bevacizumab (Avastin, Genentech/Roche) is a humanized monoclonal antibody that binds to VEGF preventing its interaction with VEGFRs resulting in suppression of VEGF signaling.” NCT03573986 ↗ “Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.” NCT01439178 ↗ “An antibody to VEGF (bevacizumab, Avastin) has demonstrated a significant prolongation of time to disease progression compared with placebo in patients with metastatic RCC.” PMID 15102658 ↗ Apr 2004 “The purpose of this research study is to learn more about whether the combination of drugs carboplatin, Abraxane and Avastin helps treat non-small cell lung cancer (NSCLC).” NCT00642759 ↗ “The treatment group were accepted intraperitoneal injection with bevacizumab (avastin) 300mg after each intraperitoneal hyperthermic perfusion chemotherapy for 6 weeks.” NCT01838538 ↗ “The goal of this clinical research study is to learn if and how Avastin (bevacizumab) may affect cancer that has spread to the meninges of the brain or the spinal cord.” NCT00924820 ↗ “The purpose of this study was to investigate the efficacy of bevacizumab ("Avastin") for the treatment of epistaxis in hereditary hemorrhagic telangiectasia (HHT).” PMID 24595923 ↗ Apr 2014 “the addition of the new anti-cancer drug bevacizumab (Avastin) to the combination of the chemotherapeutic agents capecitabine (Xeloda) and oxaliplatin (Eloxatin)” NCT00394992 ↗ “Bevacizumab (also called Avastin) has been approved by the FDA for the treatment of colon cancer, but has not been approved for the treatment of kidney cancer.” NCT00184015 ↗ “Bevacizumab (Avastin™) is an intravenous (I.V., meaning through a vein) medication made from a special type of human and mouse protein called antibodies.” NCT01055795 ↗ “A Phase II Study of Bevacizumab (Avastin™) and Erlotinib (Tarceva™) in Combination With FOLFOX for Patients With Untreated Metastatic Colorectal Cancer” NCT00116506 ↗ “Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers.” NCT00557232 ↗ “intravitreal injection of Avastin, Lucentis, and Macugen for wet age-related macular degeneration, retinal vein occlusion, and diabetic macular edema” NCT01640171 ↗ “Enroled patientswill receive 1200 mg of atezolizumab and 15mg/Kg of Avastin® (bevacizumab) administered by IV infusion every 21 days (+/- 3 days).” NCT03836066 ↗ “Prospective Phase II Study of Gemcitabine Plus Platinum Salt in Combination With Bevacizumab (Avastin®) for Metastatic Collecting Duct Carcinoma” NCT02363751 ↗ “Bevacizumab Avastin (Avastin) comes in a sterile vial (100 mg in 4 ml) preservative free and ensure safety the vial injection was within a day.” NCT00403026 ↗ “Chronic Subdural Hematoma Treatment With Avastin® (Bevacizumab) Intra-Arterial Injection: A Non-Randomized, Open-Label Phase 1/2 Clinical Trial” NCT06510582 ↗ “QL1101 is a biosimilar of bevacizumab (Avastin) produced and provided by Qilu Pharmaceutical Co., Ltd., which has been marketed in China.” NCT04527068 ↗ “The therapeutic trial of erlotinib (Tarceva) and bevacizumab (Avastin) for first-line treatment of Stage IIIB/IV or recurrent lung cancer” NCT00708448 ↗ “Another class of drugs, inhibitors of Vascular Endothelial Growth Factor (VEGF) such as bevacizumab (Avastin®), also appear efficacious.” NCT01298076 ↗ “Combination of intravitreal triamcinolone acetonide (Kenacort-AⓇ) (2mg/0.05ml) and intravitreal bevacizumab (Avastin®) (1.25mg/0.05ml)” NCT04812977 ↗ “COMBINATION OF ERIBULIN (HALAVEN®) + BEVACIZUMAB (AVASTIN®) AS A FIRST LINE TREATMENT IN PATIENTS WITH METASTATIC HER2- BREAST CANCER” NCT01941407 ↗ “A Phase I Trial of PTK787/ZK222584 in Combination With Bevacizumab (Avastin) in Patients With Refractory and/or Advanced Malignancies” NCT00611793 ↗ “Bevacizumab (Avastin) Plus Pemetrexed (Alimta) and Carboplatin in Previously Untreated Advanced Non-Small Cell Lung Cancer (NSCLC)” NCT00254319 ↗ “Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations” NCT03227263 ↗ “Phase II Study Evaluating the Efficacy of Bevacizumab (Avastin@) in Hepatocellular Carcinoma Not Amenable to Curative Treatment” NCT00162669 ↗ “Subjects will receive monthly intravitreous injections of Avacincaptad Pegol in combination with Lucentis, Avastin or Eylea.” NCT02397954 ↗ “The substances currently in clinical use include ranibizumab (Lucentis®), bevacizumab (Avastin®) and pegaptanib (Macugen®).” NCT00709657 ↗ “Repeated Superselective Intraarterial Cerebral infusion (SIACI) of Bevacizumab (Avastin) with Temozolomide and Radiation” NCT05271240 ↗ “Comparing the Pharmacokinetics, Safety and Immunogenicity of SCT510 With Bevacizumab (Avastin®) in Chinese Healthy Males” NCT05113511 ↗ “Repeated Super-selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Relapsed GBM and AA” NCT01269853 ↗ “The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions.” NCT00682539 ↗ “Phase II Study Evaluating the Efficacy and Tolerance of Bevacizumab (Avastin) in HER2- Inflammatory Breast Cancer” NCT00820547 ↗ “The therapeutic monoclonal antibody Bevacizumab (Avastin®) inhibits the VEGF pathway by binding the VEGF ligand.” NCT01144988 ↗ “oral Xeloda with intravenous (IV) Eloxatin (oxaliplatin) and IV bevacizumab (Avastin) as a first-line treatment” NCT00118755 ↗ “Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody” NCT04344782 ↗ “Bevacizumab (Avastin®) is a recombinant humanized monoclonal IgG1 antibody which binds to and neutralizes VEGF.” NCT07244705 ↗ “A Multicenter Study of the Anti-VEGF Monoclonal Antibody Bevacizumab (Avastin®) Plus 5-Fluorouracil/Leucovorin” NCT00066846 ↗ “Osimertinib, 80mg, oral daily; bevacizumab (avastin), 15mg/KG body weight, erery 21 days, intravenously.” NCT04974879 ↗ “Bevacizumab (Avastin®) is a monoclonal antibody targeting the vascular endothelial growth factor (VEGF).” PMID 36595042 ↗ Jan 2023 “A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers” NCT03576651 ↗ “tandutinib and bevacizumab (Avastin, Genentech, South San Francisco, CA) for glioblastoma (NCT00667394)” PMID 21242491 ↗ Jan 2011 “In addition Bevacizumab (Avastin) is to be administered as early as possible during the disease stages” NCT01985841 ↗ “This study will also test the safety of adding a 3rd drug called bevacizumab (also known as Avastin).” NCT00588237 ↗ “A Phase II Trial Of Avastin (Bevacizumab) In Patients With Metastatic Papillary Renal Cell Carcinoma” NCT00601926 ↗ “2. Avastin, (L01FG01), bevacizumab, intravenous administration (administered as standard of care).” NCT07645625 ↗ “compare the effectiveness of bevacizumab (Avastin) with another a dexamethasone implant (Ozurdex)” NCT04067856 ↗ “Monoclonal antibodies, such as bevacizumab (Avastin™), can block cancer growth in different ways.” NCT00062426 ↗ “Eloxatin (Oxaliplatin) + Leucovorin (Folinic acid) + 5-FU (Fluorouracil) + Avastin (Bevacizumab)” NCT02574663 ↗ “Group A received an intralesional injection of bevacizumab (Avastin), one month before surgery.” NCT05314673 ↗ “Bevacizumab Avastin (Avastin) is available in a sterile vial (100 mg in 4 ml) preservative free” NCT00468429 ↗ “three medications given together: paclitaxel, pemetrexed (Alimta®), and bevacizumab (Avastin®).” NCT00807573 ↗ “Bevacizumab as Avastin 15 mg/kg IV + Carboplatin AUC 6 IV+ Paclitaxel 200 or 175 mg/m2 IV” NCT04633564 ↗ “FOLFIRI + Avastin and during the chemotherapy-free interval maintenance with bevacizumab” NCT00952029 ↗ “Multifocal Electrophysiologic Findings After Intravitreal Bevacizumab(Avastin)Treatment” NCT00417833 ↗ “concomitant Avastin (Bevacizumab) 15mg/kg q 3weeks for treatment duration of one year.” NCT00911716 ↗ “Bevacizumab (Avastin, genentech, Inc., San Francisco, California, the USA) is a drug.” NCT00496405 ↗ “Avastin (bevacizumab) treatment combined with transarterial chemoembolisation (TACE)” NCT00576199 ↗ “Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months” NCT01015300 ↗ “The bevacizumab-Avastin® adjuVANT (AVANT) study did not meet its primary end point” PMID 31959341 ↗ Dec 2019 “Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)” NCT01422018 ↗ “reference bevacizumab (Avastin®) sourced from the European Union (bevacizumab-EU)” PMID 31768697 ↗ Nov 2019 “Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma” NCT00137826 ↗ “bevacizumab (Avastin), an antibody targeting vascular endothelial growth factor” NCT00390026 ↗ “intravitreal injection of bevacizumab (Avastin, Roche, Rio de Janeiro, Brazil)” NCT00556348 ↗ “Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS” NCT01017250 ↗ “Intravitreal Bevacizumab (Avastin) for Pseudophakic Macular Edema (PME)” NCT00406172 ↗ “BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors” NCT00095459 ↗ “the leader of which is bevacizumab (Avastin®, Roche, Bale, Switzerland)” NCT04813913 ↗ “On the first four treatments you will also get Bevacizumab (Avastin).” NCT00826800 ↗ “Arm B: Cisplatin, Paclitaxel, Gemcitabine and Avastin (Bevacizumab)” NCT00458315 ↗ “Bevacizumab (Avastin) is a humanized monoclonal antibody to VEGF.” NCT00888043 ↗ “primary 2.5 mg injection of Bevacizumab (Avastin) intravitreally” NCT00599820 ↗ “Atezolizumab (Tecentriq®) + Bevacizumab (Avastin®)+β- alanine” NCT07317414 ↗ “capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)” NCT00447330 ↗ “Bevacizumab (Avastin) is a potent inhibitor of angiogenesis” NCT01091896 ↗ “Bevacizumab(Avastin, Genentech, Inc., South San Francisco)” NCT01920984 ↗ “another drug called bevacizumab (also known as Avastin)” NCT01223235 ↗ “bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil)” NCT00797303 ↗ “* BIBW 2992 and paclitaxel and bevacizumab (Avastin)” NCT00809133 ↗ “Avastin (Bevacizumab) administered intravitreally” NCT01787669 ↗ “The Effect of Bevacizumab (Avastin) on Pterygium” NCT00592176 ↗ “Bevacizumab (Avastin) 15 mg/kg IV, every 21 days” NCT00932152 ↗ “Bevacizumab (Avastin) intra-articular injection” NCT02060305 ↗ “intravitreal injection of Bevacizumab (Avastin)” NCT00531336 ↗ “Intravitreal injection of bevacizumab (Avastin)” NCT01823081 ↗ “Bevacizumab (Avastin), Verteporfin (Visudyne)” NCT00696592 ↗ “Bevacizumab (Avastin), Oxaliplatin (Eloxatin)” NCT00398320 ↗ “Erlotinib (Tarceva) and Bevacizumab (Avastin)” NCT00749567 ↗ “Standard Chemotherapy + bevacizumab (Avastin)” NCT00651456 ↗ “intravitreal bevacizumab (Avastin) injection” NCT00423059 ↗ “Avastin (Bevacizumab for triple negative)” NCT01426880 ↗ “Bevacizumab (aka Avastin or Rhu MAb VEGF)” NCT00047762 ↗ “Bevacizumab (Avastin; Genentech, Inc.)” NCT01256580 ↗ “Bevacizumab (also called Avastin™)” NCT00597506 ↗ “intravenous Avastin (bevacizumab)” NCT02013830 ↗ “Bevacizumab (tradename: Avastin)” NCT00344617 ↗ “Bevacizumab Injection [Avastin]” NCT05514925 ↗ “Bevacizumab Injection [Avastin]” NCT03211741 ↗ “Bevacizumab Injection [Avastin]” NCT06559488 ↗ “Bevacizumab Injection [Avastin]” NCT06850571 ↗ “Drug: Bevacizumab (Avastin®)” NCT01201850 ↗ “Drug: bevacizumab [Avastin]” NCT00520403 ↗ “Drug: bevacizumab [Avastin]” NCT02005549 ↗ “Bevacizumab (Avastin®)” NCT00296816 ↗ “Bevacizumab (Avastin®)” NCT03390673 ↗ “Bevacizumab (Avastin)” NCT01083966 ↗ “Bevacizumab (Avastin)” NCT00395434 ↗ “bevacizumab [Avastin]” NCT01227707 ↗ “bevacizumab [Avastin]” NCT01308684 ↗ “bevacizumab [Avastin]” NCT00717405 ↗ “bevacizumab [Avastin]” NCT00773188 ↗ “Avastin (bevacizumab)” NCT00698516 ↗ “bevacizumab [Avastin]” NCT00349336 ↗ “Bevacizumab (Avastin)” NCT00242502 ↗ “bevacizumab [Avastin]” NCT00811135 ↗ “bevacizumab [Avastin]” NCT00964704 ↗ “bevacizumab [Avastin]” NCT00796757 ↗ “Bevacizumab (Avastin)” NCT00862342 ↗ “Avastin (bevacizumab)” NCT00109070 ↗ “bevacizumab [Avastin]” NCT00700180 ↗ “Avastin (bevacizumab)” NCT00095225 ↗ “bevacizumab [Avastin]” NCT01159171 ↗ “bevacizumab [Avastin]” NCT00700570 ↗ “Bevacizumab (Avastin)” NCT01331616 ↗ “bevacizumab [Avastin]” NCT00929240 ↗ “bevacizumab [Avastin]” NCT00559754 ↗ “Bevacizumab (Avastin)” NCT00906516 ↗ “bevacizumab [Avastin]” NCT00448136 ↗ “Avastin (bevacizumab)” NCT02810457 ↗ “bevacizumab [Avastin]” NCT00642577 ↗ “bevacizumab [Avastin]” NCT00845910 ↗ “Bevacizumab (avastin)” NCT00615056 ↗ “bevacizumab [Avastin]” NCT01250379 ↗ “bevacizumab [Avastin]” NCT00642603 ↗ “Bevacizumab (Avastin)” NCT00675597 ↗ “bevacizumab [Avastin]” NCT01077739 ↗ “bevacizumab [Avastin]” NCT01496742 ↗ “bevacizumab (Avastin)” NCT00515684 ↗ “Bevacizumab [Avastin]” NCT00738530 ↗ “bevacizumab [Avastin]” NCT00940303 ↗ “bevacizumab [Avastin]” NCT00967330 ↗ “bevacizumab [Avastin]” NCT01077713 ↗ “Avastin (bevacizumab)” NCT01531595 ↗ “bevacizumab (Avastin)” NCT00337389 ↗ “bevacizumab [Avastin]” NCT01069627 ↗ “Avastin (Bevacizumab)” NCT01338558 ↗ “bevacizumab [Avastin]” NCT00776698 ↗ “bevacizumab [Avastin]” NCT01474239 ↗ “bevacizumab [Avastin]” NCT00778102 ↗ “bevacizumab [Avastin]” NCT01135498 ↗ “Bevacizumab (Avastin)” NCT00555594 ↗ “Avastin (bevacizumab)” NCT00081614 ↗ “Bevacizumab (Avastin)” NCT00271505 ↗ “bevacizumab [Avastin]” NCT00806923 ↗ “Bevacizumab (Avastin)” NCT00416637 ↗ “bevacizumab [Avastin]” NCT00404703 ↗ “bevacizumab [Avastin]” NCT01115491 ↗ “Bevacizumab [Avastin]” NCT00451906 ↗ “bevacizumab [Avastin]” NCT01181609 ↗ “bevacizumab [Avastin]” NCT01156961 ↗ “bevacizumab [Avastin]” NCT00642824 ↗ “Bevacizumab (Avastin)” NCT00512876 ↗ “bevacizumab [Avastin]” NCT00577031 ↗ “bevacizumab [Avastin]” NCT00577109 ↗ “bevacizumab [Avastin]” NCT01214720 ↗ “bevacizumab (Avastin)” NCT00598156 ↗ “bevacizumab [Avastin]” NCT00774241 ↗ “bevacizumab [Avastin]” NCT00925769 ↗ “bevacizumab - Avastin” NCT00819754 ↗ “Drug: Avastin” NCT01231633 ↗ |
| Known as | Avastin: bevacizumab. | “Avastin® (bevacizumab)” NCT00365365 ↗10“Avastin® (bevacizumab)” NCT01295112 ↗ “Avastin: bevacizumab.” NCT00462423 ↗ “Avastin (bevacizumab)” NCT01434147 ↗ “Avastin (bevacizumab)” NCT00979017 ↗ “Avastin (bevacizumab)” NCT01531595 ↗ “Avastin - Bevacizumab” NCT00612339 ↗ “Avastin (bevacizumab)” NCT01186406 ↗ “Avastin(BEVACIZUMAB)” NCT02594423 ↗ “Avastin (Bevacizumab” NCT00845884 ↗ “Avastin, bevacizumab” NCT01231633 ↗ |
| Known as | AvastinR | “Chemotherapy With FOLFIRI Plus Bevacizumab (AvastinR) in Patients With Metastatic Colorectal Cancer Bearing Genotype UGT1A1*1/UGT1A1*1 or UGT1A1*1/UGT1A1*1/UGT1A1*28:...” NCT00628810 ↗ |
| Known as | Avastinâ | “Phase II Study of the A-ICOX Regimen Consisting of Bevacizumab (Avastinâ), Intermittent Dose Capecitabine (Xelodaâ) and Oxaliplatin (Eloxatinâ) in Patients With Untreated...” NCT00177307 ↗ |
| Known as | AvastinÒ | “Bevacizumab (AvastinÒ) will be given intravenously at 10 mg/kg every other week.” NCT00350753 ↗ |
| Known as | Avatstin | “Bevicizumab (Avatstin) is a humanized monoclonal antibody to VEGF.” NCT00586443 ↗ |
| Known as | BE1040V | “Efficacy and Safety of Proposed Bevacizumab Biosimilar BE1040V in Patients With Metastatic Colorectal Cancer” PMID 32334845 ↗ Apr 2020 |
| Known as | Bev | “Based on the synergistic potential of radiotherapy and angiogenesis inhibitors, we initiated this phase II study to assess the efficacy and safety of combining bevacizumab...” PMID 41235462 ↗ Nov 202523“Participants in the atezolizumab plus bevacizumab (Atezo + Bev) arm will receive up to three 3 atezolizumab doses (days 10, 31, 52) and 2 bevacizumab dose (days 10 and 31)...” NCT07018947 ↗ “The ARTemis trial previously reported that addition of neoadjuvant bevacizumab (Bev) to docetaxel (D) followed by fluorouracil, epirubicin and cyclophosphamide (D-FEC) in HER2...” PMID 28459938 ↗ Aug 2017 “Neoadjuvant therapy consists of three cycles of HAIC combined with atezolizumab and bevacizumab (atezo/bev), while adjuvant therapy includes two cycles of HAIC combined with...” NCT06739252 ↗ “This will be a prospective, open-label, single-arm pilot study to investigate the safety and efficacy of Bevacizumab (BEV) in combination with microbubble (MB)-mediated FUS in...” NCT06329570 ↗ “Bevacizumab (Bev) is an antiangiogenic monoclonal antibody targeting VEGF (vascular endothelial growth factor) that is currently used in recurrent GBM, particularly in...” NCT02898012 ↗ “This randomized phase II-III trial sought to evaluate the efficacy and safety of adding bevacizumab (Bev) following induction chemotherapy (CT) in extensive small-cell lung...” PMID 25688059 ↗ Feb 2015 “Bevacizumab (BEV), a monoclonal antibody against vascular endothelial growth factor-A (VEGF-A), is a standard component of medical therapy of metastatic colorectal cancer (mCRC).” PMID 32201506 ↗ Mar 2020 “Atezolizumab (Atez) combined with bevacizumab (Bev) is the recommended first-line treatment for unresectable hepatocellular carcinoma (HCC).” PMID 40891895 ↗ Sep 2025 “Bevacizumab (Bev), an anti-tumor angiogenesis monoclonal antibody, combined with chemotherapy has been shown effective in advanced GC.” NCT02048540 ↗ “CAPIRI+bevacizumab (Bev) in comparison with FOLFIRI+Bev as first-line treatment for patients with metastatic colorectal cancer (mCRC).” PMID 22240792 ↗ Jan 2012 “Perioperative chemotherapy with bevacizumab (BEV) may improve the outcome of these patients.” PMID 26673788 ↗ Dec 2015 “Patients receive bevacizumab (bev) IV on day 1 and docetaxel every 3 weeks” NCT00408408 ↗ “bevacizumab (Bev) as second-line treatment for advanced colorectal cancer” NCT07047560 ↗ “bevacizumab (BEV) to preoperative capecitabine (CAP)-based CRT in LARC” PMID 25886378 ↗ Feb 2015 “intravenous infusion (IV) of Bevacizumab (Bev.) (15mg/kg, IV, Q3W)” NCT06737913 ↗ “maintenance bevacizumab plus exemestane (E + BEV)” PMID 26916095 ↗ Feb 2016 “Bevacizumab (BEV): 5mg/kg (d.i.v.);” NCT04160416 ↗ “bevacizumab (Bev), or bev alone” NCT07059845 ↗ “bevacizumab (BEV)” NCT07274787 ↗ “Bevacizumab (Bev)” NCT07150208 ↗ “Bevacizumab (Bev)” NCT00612586 ↗ “bevacizumab (Bev)” PMID 21677464 ↗ Jun 2011 “BEV(bevacizumab)” NCT07669610 ↗ |
| Known as | Bevacizumab (Avastin) | “bevacizumab ( Avastin )” NCT00681603 ↗21“Bevacizumab (Avastin )” NCT01195298 ↗ “Bevacizumab (Avastin™)” NCT00604461 ↗ “bevacizumab (Avastin®)” NCT01067053 ↗ “Bevacizumab (Avastin).” NCT02072720 ↗ “Bevacizumab (Avastin)” NCT00635050 ↗ “Bevacizumab (Avastin)” NCT01588704 ↗ “Bevacizumab (Avastin)” NCT01516216 ↗ “Bevacizumab (Avastin)” NCT02348359 ↗ “Bevacizumab (Avastin)” NCT00939991 ↗ “Bevacizumab = Avastin” NCT00359164 ↗ “Bevacizumab - Avastin” NCT00612430 ↗ “Bevacizumab: Avastin®” NCT00585377 ↗ “bevacizumab (Avastin)” NCT01116219 ↗ “Bevacizumab (Avastin)” NCT01115517 ↗ “Bevacizumab (Avastin)” NCT01281696 ↗ “Bevacizumab (Avastin)” NCT00161291 ↗ “Bevacizumab (Avastin)” NCT03585556 ↗ “Bevacizumab（Avastin）” NCT01621880 ↗ “bevacizumab: avastin” NCT01025349 ↗ “bevacizumab :avastin” NCT01141881 ↗ “Bevacizumab/Avastin” NCT00517595 ↗ |
| Known as | Bevacizumab (Avastin;Genentech Inc,USA) | “Bevacizumab (Avastin;Genentech Inc,USA)” NCT02015351 ↗ |
| Known as | Bevacizumab (BP102) | “Bevacizumab (BP102)” NCT04395989 ↗1“Bevacizumab (BP102)” NCT05806060 ↗ |
| Known as | Bevacizumab (rhuMAb VEGF, Avastin), NSC 704865 | “Bevacizumab (rhuMAb VEGF, Avastin), NSC 704865” NCT00891527 ↗ |
| Known as | bevacizumab biosimilar | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04670978 ↗ |
| Known as | Bevacizumab Biosimilar CBT 124 | “Bevacizumab Biosimilar CBT 124” NCT00408694 ↗ |
| Known as | Bevacizumab Injection | “Bevacizumab injection (intravenous infusion, 7.5 mg/kg) administered every 21 days as one cycle, for a total of 2 cycles.” NCT07182708 ↗ |
| Known as | Bevacizumab Richmond | “Zutrab® (Bevacizumab Richmond)” NCT03919448 ↗ |
| Known as | Bevacizumab+ chemotherapy | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05555901 ↗ |
| Known as | Bevacizumab- also known as Avastin | “Bevacizumab- also known as Avastin” NCT00790010 ↗ |
| Known as | bevacizumab-800CW | “The purpose of this study was to determine the safety and feasibility of fluorescence molecular imaging using a commercially available system and intravenous injection of...” PMID 41344859 ↗ Jan 2026 |
| Known as | Bevacizumab-awwb | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06252649 ↗ |
| Known as | Bevacizumab-EU | “reference bevacizumab (Avastin®) sourced from the European Union (bevacizumab-EU)” PMID 31768697 ↗ Nov 20192“maintenance monotherapy with Bevacizumab-EU up to a maximum of 8 months.” NCT03329911 ↗ |
| Known as | Bmab | “Bevacizumab (Bmab)” NCT02497157 ↗ |
| Known as | Brand name of Bevacizumab is Avastin | “Brand name of Bevacizumab is Avastin” NCT00548197 ↗ |
| Known as | BVC | “Association of Bevacizumab (BVC)+ Pazopanib (PZP)” NCT01202032 ↗ |
| Known as | BVZ | “Bevacizumab, BVZ (group A)” NCT06952452 ↗ |
| Known as | China-approved Avastin | “China-approved Bevacizumab® (Also Called China-approved Avastin)” NCT05378867 ↗ |
| Known as | Cizumab | “The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two...” NCT03919448 ↗ |
| Known as | CN-Avastin | “CN-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.” NCT03483649 ↗ |
| Known as | Dalutin | “Dalutin ® Bevacizumab 15mg/kg IV” NCT06590844 ↗ |
| Known as | Dayoutong injection | “bevacizumab (Dayoutong injection, 15 mg/kg)” NCT06995105 ↗ |
| Known as | EO4010 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05589597 ↗ |
| Known as | EU-Avastin | “EU-Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.” NCT03483649 ↗1“Drug: EU Avastin® 15 mg/kg IV infusions” NCT03329911 ↗ |
| Known as | EU-bevacizumab | “BACKGROUND: MB02 (bevacizumab biosimilar) showed similar structural, functional, and pharmacokinetic properties to reference bevacizumab (Avastin®; EU-bevacizumab).” PMID 33914256 ↗ Apr 2021 |
| Known as | HLX04 | “AIM: To evaluate the efficacy and safety of HLX04-O, an investigational ophthalmic formulation of HLX04 (bevacizumab biosimilar) for intravitreal injection, as a treatment for...” PMID 36124180 ↗ Sep 2022 |
| Known as | HLX04 ( anti-VEGF antibody ) | “HLX04 ( anti-VEGF antibody )” NCT04465734 ↗ |
| Known as | HLX04-O | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04740671 ↗ |
| Known as | IBI305 | “Bevacizumab Biosimilar IBI305” NCT05355155 ↗ |
| Known as | Intra-vitreal Anti-VEGF Drug | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01640171 ↗ |
| Known as | Intravitreal bevacizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02663141 ↗ |
| Known as | IVB | “The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a...” NCT00802126 ↗6“OBJECTIVE: To determine the efficacy of intravitreal bevacizumab (IVB) monotherapy versus a combination of IVB and suprachoroidal triamcinolone acetonide (SCTA) followed by...” PMID 42369925 ↗ Jun 2026 “comparing intravitreal bevacizumab (IVB) injection alone or in combination with intravitreal triamcinolone acetonide (IVT) versus macular laser photocoagulation (MPC) as a...” PMID 22234244 ↗ Feb 2012 “To evaluate the effect of three intravitreal injections of bevacizumab (IVB) alone or combined with triamcinolone (IVT) in the first injection for treatment of refractory...” PMID 17917738 ↗ Oct 2007 “PURPOSE: To compare the anatomical and functional outcomes of treatment with intravitreal bevacizumab (IVB) and topical timolol-dorzolamide versus IVB alone.” PMID 38376643 ↗ Feb 2024 “intravitreal bevacizumab (IVB) group with four monthly IVB injections” PMID 35594075 ↗ Jun 2022 “intravitreal bevacizumab (IVB)” PMID 31401683 ↗ Aug 2019 |
| Known as | Lumiere | “The purpose of this clinical trial is to evaluate the safety and clinical effectiveness of intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of...” NCT03668054 ↗ |
| Known as | MRG006A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07479485 ↗ |
| Known as | MVASI | “MVASI® (bevacizumab-awwb) administered as an IV infusion.” NCT04185883 ↗ |
| Known as | Nelmastobart in combination with TAS-102 and Bevacizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07656038 ↗ |
| Known as | NSC #704865 | “A Dose-Escalating Phase I Study With an Expanded Cohort to Assess the Feasibility of Intraperitoneal Carboplatin (NSC #214240) and Intravenous Paclitaxel (NSC # 673089) and...” NCT00079430 ↗5“The Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC # 704865, IND # 7,921) Administered in Times Sequential...” NCT00015951 ↗ “A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and...” NCT00436332 ↗ “Phase III Prospective Randomized Comparison of Depot Octreotide Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC #704865) in Advanced, Poor Prognosis...” NCT00569127 ↗ “A Multi-Institutional, Open-Label, Phase II Study Of Doxorubicin And Bevacizumab (Anti-VEFG Monoclonal Antibody, NSC 704865) For Patients With Advanced Or Metastatic Soft-Tissue Sarcoma” NCT00052390 ↗ “A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas” NCT00445848 ↗ |
| Known as | Onbevzi | “bevacizumab (Onbevzi) at a dose of 15 mg/kg administered as a 30-minute intravenous infusion on Day 1 of each 21-day cycle” NCT07547592 ↗ |
| Known as | PRO-169 | “A total of 442 patients with diabetic macular edema will be randomized 1:1 to be treated with either PRO-169 (bevacizumab) or Lucentis® (ranibizumab).” NCT05217680 ↗ |
| Known as | R435 | “R435 (Bevacizumab) in Combination With Paclitaxel” NCT00467012 ↗ |
| Known as | rhuMAB-VEGF | “The Recombinant Human Monoclonal Anti-Vascular Endothelial Growth Factor Antibody (rhuMAB VEGF) Bevacizumab (NSC # 704865, IND # 7,921) Administered in Times Sequential...” NCT00015951 ↗11“This is a pilot study in patients with previously untreated inflammatory breast cancer (IBC) or locally advanced breast cancer (LABC) to evaluate angiogenesis parameters after...” NCT00016549 ↗ “A Phase III, Multicenter, Randomized, Active-Controlled Clinical Trial to Evaluate the Efficacy and Safety of rhuMAb VEGF (Bevacizumab) in Combination With Standard...” NCT00109070 ↗ “A Phase II Trial of the Combination of OSI-774 (ERLOTINIB; NSC-718781) and Bevacizumab (Rhumab VEGF; NSC-704865) in Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and...” NCT00436332 ↗ “rhuMAB-VEGF,bevacizumab: 10 mg/kg by intravenous infusion over 30-90 minutes once every 2 weeks docetaxel, Taxotere: 35 mg/m2 given intravenously over 1 hour on days 1, 8, and...” NCT00066677 ↗ “A Phase II Trial of the Combination of OSI-774 (Erlotinib; NSC-718781) and Bevacizumab (RHUMAB VEGF; NSC 704865) in Never-Smokers With Stage IIIB and IV Primary NSCLC Adenocarcinomas” NCT00445848 ↗ “The purpose of this study is to determine whether rhuMAb VEGF (Bevacizumab) is safe and effective for the treatment of renal cell cancer when other treatments have failed.” NCT00061178 ↗ “A Phase 2 Study Of Neoadjuvant rhuMAb VEGF (Bevacizumab) In Combination With Paclitaxel And Carboplatin In Surgically Resectable Non-Small Cell Lung Cancer” NCT00025389 ↗ “Bevacizumab (aka Avastin or Rhu MAb VEGF)” NCT00047762 ↗ “rhuMAb VEGF (Bevacizumab)” NCT00109239 ↗ “rhuMAb VEGF” NCT01212822 ↗ “rhuMAb-VEGF” NCT00980239 ↗ |
| Known as | Sequential AG and mFOLFOX in Combination With Serplulimab and Bevacizumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07235930 ↗ |
| Known as | Stivant | “Comparing Efficacy and Safety of Stivant (AryoGen Bevacizumab) Versus Avastin in Metastatic Colorectal Cancer” NCT03288987 ↗ |
| Known as | US-Avastin | “US Avastin®: Supplied as 100 mg/4 mL solution; reconstituted to 100 mL with 0.9% sodium chloride; a single dose of 3 mg/kg will be administered intravenously for 90 minutes.” NCT03483649 ↗ |
| Known as | ZERIBEV | “Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody” NCT04344782 ↗ |
| Known as | Zirabev | “Bevacizumab (Zirabev®) is administered at a dose of 15mg/kg, i.v. every 3 weeks, until disease progression, or intolerable toxicity.” NCT05601973 ↗1“EFFICACY and SAFETY OF BEVACIZUMAB (ZIRABEV®) IN PATIENTS WITH SEVERE HYPOXEMIC COVID-19” NCT04822818 ↗ |
| Known as | Zutrab | “The aim of the Clinical study is to evaluate the pharmacokinetic and safety profile of a new formulation of Bevacizumab (Zutrab®, Argentinian origin) when compared to two...” NCT03919448 ↗ |
| Action | Inhibit | “vascular endothelial growth factor is optimally inhibited” NCT00005061 ↗ |
| Modality | Monoclonal antibody | “Humanized Anti-VEGF Monoclonal Antibody” NCT00005061 ↗ |
| Route | Intravenous | “Patients receive monoclonal antibody VEGF (MOAB VEGF) IV over 1 hour” NCT00005061 ↗ |
| Target | VEGFA | “rhuMAb VEGF - recombinant humanized monoclonal antibody vascular endothelial growth factor (bevacizumab)” NCT00016549 ↗ |